Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocugen, Inc. Receives Orphan Medicinal Product Designation from EMA for OCU410ST in Treating ABCA4-Associated Retinopathies Quiver Quantitative, Inc. - Wed Nov 20, 4:48PM CST

Ocugen's OCU410ST receives orphan designation from EMA for treating rare retinal diseases, advancing towards clinical trials and potential market approval.Quiver AI SummaryOcugen, Inc. announced that the...

OCGN : 0.9009 (-1.92%)
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease GlobeNewswire - Wed Nov 20, 6:30AM CST

OCGN : 0.9009 (-1.92%)
Ocugen, Inc. Reports Positive Preliminary Data from OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration Quiver Quantitative, Inc. - Tue Nov 19, 4:16PM CST

Ocugen announced positive early results for OCU410 in treating geographic atrophy, showing safety and efficacy.Quiver AI SummaryOcugen, Inc. announced promising preliminary results from the Phase 1 dose-escalation...

OCGN : 0.9009 (-1.92%)
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire - Tue Nov 19, 6:02AM CST

OCGN : 0.9009 (-1.92%)
Trader at office - by Viktoriia Hnatiuk via Shutterstock
Wall Street Expects These 2 Under-the-Radar Growth Stocks to Outperform Barchart - Fri Nov 15, 7:21AM CST

The recent quarterly results of these two growth stocks show that they have significant long-term growth potential.

MSFT : 412.87 (-0.43%)
META : 563.09 (-0.43%)
MNDY : 276.26 (+6.19%)
$SPX : 5,948.71 (+0.53%)
OCGN : 0.9009 (-1.92%)
Ocugen: Q3 Earnings Snapshot AP - Thu Nov 14, 2:32PM CST

Ocugen: Q3 Earnings Snapshot

OCGN : 0.9009 (-1.92%)
Ocugen (OCGN) Q3 2024 Earnings Call Transcript Motley Fool - Fri Nov 8, 10:15AM CST

OCGN earnings call for the period ending September 30, 2024.

OCGN : 0.9009 (-1.92%)
Ocugen Provides Business Update with Third Quarter 2024 Financial Results GlobeNewswire - Fri Nov 8, 5:45AM CST

OCGN : 0.9009 (-1.92%)
Ocugen Secures $30 Million in Debt Funding GlobeNewswire - Thu Nov 7, 5:30AM CST

OCGN : 0.9009 (-1.92%)
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 GlobeNewswire - Mon Oct 28, 5:30AM CDT

OCGN : 0.9009 (-1.92%)

Barchart Exclusives

Recent Corn Rally Artificially Propped Up – What’s Next? Barchart - 6 minutes ago
Corn prices appeared to have finally found a bottom from the summer sell-off. Speculators were short the market in record numbers until late August, when they began buying back contracts, convincing some that the harvest seasonal low may be in. Then, exports increased in the last few weeks, and prices rallied more. While the bearish fundamentals of 1.9 billion carry-out and the massive amount of unpriced corn still linger, there isn’t much hope for a significant price rally yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot